Douglas S. Ingram, President & CEO at Sarepta Therapeutics, Inc. (SRPT), bought 16,000 shares at $125.26 ($2.0M) on 2018-08-15, disclosed to the SEC on 2018-08-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| RLAY | BUY | 2020-07-21 | $500K | — | Filing → |
| SRPT | BUY | 2019-08-12 | $4.0M | — | Filing → |
| SRPT | BUY | 2018-10-30 | $4.0M | — | Filing → |